- Home
- ELTK vs GNLX Comparison
ELTK vs GNLX Comparison
Compare ELTK & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTK
- GNLX
- Stock Information
- Founded
- ELTK 1970
- GNLX 2001
- Country
- ELTK Israel
- GNLX United States
- Employees
- ELTK N/A
- GNLX N/A
- Industry
- ELTK Electrical Products
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ELTK Technology
- GNLX Health Care
- Exchange
- ELTK Nasdaq
- GNLX Nasdaq
- Market Cap
- ELTK 73.9M
- GNLX 85.0M
- IPO Year
- ELTK 1997
- GNLX 2023
- Fundamental
- Price
- ELTK $11.40
- GNLX $3.96
- Analyst Decision
- ELTK
- GNLX Strong Buy
- Analyst Count
- ELTK 0
- GNLX 4
- Target Price
- ELTK N/A
- GNLX $18.25
- AVG Volume (30 Days)
- ELTK 13.1K
- GNLX 193.5K
- Earning Date
- ELTK 03-10-2025
- GNLX 11-14-2024
- Dividend Yield
- ELTK 1.92%
- GNLX N/A
- EPS Growth
- ELTK N/A
- GNLX N/A
- EPS
- ELTK 0.85
- GNLX N/A
- Revenue
- ELTK $48,090,000.00
- GNLX $8,000.00
- Revenue This Year
- ELTK $7.47
- GNLX N/A
- Revenue Next Year
- ELTK $9.96
- GNLX N/A
- P/E Ratio
- ELTK $13.23
- GNLX N/A
- Revenue Growth
- ELTK 7.22
- GNLX N/A
- 52 Week Low
- ELTK $9.00
- GNLX $1.60
- 52 Week High
- ELTK $22.80
- GNLX $12.12
- Technical
- Relative Strength Index (RSI)
- ELTK 56.29
- GNLX 79.63
- Support Level
- ELTK $10.86
- GNLX $3.03
- Resistance Level
- ELTK $11.35
- GNLX $3.47
- Average True Range (ATR)
- ELTK 0.32
- GNLX 0.32
- MACD
- ELTK 0.03
- GNLX 0.15
- Stochastic Oscillator
- ELTK 90.67
- GNLX 89.54
About ELTK Eltek Ltd.
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnects. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.